The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent

European Journal of Cancer

Volumn 43, Issue 3, 2007, Pages 527-535

  Baak, Jan P A ^a,b,c   van Diest, Paul J ^a   Voorhorst, Feja J ^a   van der Wall, Elsken ^a   Beex, Louk V A M ^d   Vermorken, Jan B ^e   Janssen, Emiel A M ^b   Gudlaugsson, Einar ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Age; Breast cancer; Mitotic index; Prognosis; Proliferation

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS;

EID: 33846562905     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.10.001     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Silvestrini R., Daidone M.G., Di Fronzo G., Morabito A., Valagussa P., and Bonadonna G. Prognostic implication of labeling index versus estrogen receptors and tumour size in node-negative breast cancer. Breast Cancer Res Treat 7 (1986) 161-169
3. Sigurdsson H., Baldetorp B., Borg A., et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 322 (1990) 1045-1053
4. Bergers E., van Diest P.J., and Baak J.P.A. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: results from the multicenter morphometric mammary carcinoma project. Int J Cancer 74 (1997) 260-269
5. Baak J.P.A., van Dop H., Kurver P.H.J., and Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 56 (1985) 374-382
6. Tosi P., Luzi P., Sforza V., et al. Correlation between morphometrical parameters and disease-free survival in ductal breast cancer treated only by surgery. Appl Pathol 4 (1986) 33-42
7. van der Linden J.C., Baak J.P., Lindeman J., Hermans J., and Meyer C.J. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol 40 (1987) 302-306
8. Uyterlinde A.M., Baak J.P.A., Schipper N.W., et al. Prognostic value of morphometric and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer 48 (1991) 173-181
9. Baak J.P., Colpaert C.G., van Diest P.J., et al. Multivariate prognostic evaluation of the mitotic activity index and Fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 41 (2005) 2093-2101
10. van Diest P.J., van der Wall E., and Baak J.P. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57 (2004) 675-681
11. Thor A.D., Liu S., Moore II D.H., and Edgerton S.M. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17 (1999) 470-477
12. Groenendijk R.P., Bult P., Noppen C.M., Voetes C., Ruers T.J., and Wobbes T. Mitotic activity index in interval breast cancers. Eur J Surg Oncol 29 (2003) 29-31
13. Manders P., Bult P., Sweep C.G., Tjan-Heijnen V.C., and Beek L.V. The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. Breast Cancer Res Treat 77 (2003) 77-84
14. Meyer J.S., Alvarez C., Milikowski C., et al. Cooperative Breast Cancer Tissue Resource: Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 18 8 (2005) 1067-1078
15. Volpi A., Bacci F., Paradiso A., et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol 17 9 (2004) 1038-1044
16. Baak J.P., van Diest P.J., Voorhorst F.J., et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23 25 (2005) 5993-6001
17. Andre F., Khalil A., Slimane K., et al. Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol 23 13 (2005) 2996-3000
18. Amadori D., Nanni O., Marangolo M., et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18 (2000) 3125-3134
19. Fiets W.E., Bellot F.E., Struikmans H., Blankenstein M.A., and Nortier J.W. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours. Eur J Surg Oncol 31 2 (2005) 128-133
20. Westenend P.J., Meurs C.J., and Damhuis R.A. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol 58 2 (2005) 196-201
21. Jannink I., van Diest P.J., and Baak J.P.A. Comparison of the prognostic value of mitotic frequency and mitotic activity index in breast cancer. Breast 5 (1996) 31-36
22. van Diest P.J., Baak J.P.A., Matze-Cok P., et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23 (1992) 603-607
23. Baak J.P.A., van Diest P.J., Ariens A., et al. The multicenter morphometric mammary carcinoma project (MMMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185 (1989) 664-670
24. World Health Organization. Histologic typing of breast tumors. second ed. (1981), World Health Organization, Geneva
25. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
26. Ellis I.O., Schnitt S.J., Sastre-Garau X., et al. Invasive breast carcinoma. In: Tavassoli F.A., and Devilee P. (Eds). Pathology and genetics of tumours of the breast and female genital tract organs (2003), IARC Press, Lyon 18-19
27. Jannink I., van Diest P.J., and Baak J.P.A. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol 26 (1995) 1086-1092
28. Eppenberger-Castori S., Moore Jr. D.H., Thor A.D., et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34 (2002) 1318-1330
29. Baak J.P., and Persijn J.P. In search for the best qualitative microscopical or morphometrical predictor of oestrogen receptor in breast cancer. Pathol Res Pract 178 (1984) 307-314
30. Wittliff J.L., Pasic R., and Bland K.I. Steroid and peptide hormone receptors: methods, quality control and clinical use. In: Bland K.I., and Copeland III E.M. (Eds). The breast, comprehensive management of benign and malignant diseases, 2e (1998), WB Saunders Cie, Philadelphia, PA 458-498
31. Jarvinen T.A., Pelto-Huikko M., Holli K., and Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156 (2000) 29-35
32. Janssen EAM, Van Diest PJ, Søiland H, et al. Success factors of adjuvant chemotherapyin node-negative breast cancer patients under 55 years. Cell Oncol 2006, accepted for publication.
33. Louwman W.J., van Beek M.W., Schapers R.F., et al. Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to Mitotic Activity Index: a population-based study. Int J Cancer 118 (2006) 2310-2314